TY - JOUR
T1 - Modification of 35% carbon dioxide hypersensitivity across one week of treatment with clomipramine and fluvoxamine
T2 - A double-blind, randomized, placebo-controlled study
AU - Perna, Giampaolo
AU - Bertani, Angelo
AU - Gabriele, Angela
AU - Politi, Ernestina
AU - Bellodi, Laura
PY - 1997/6
Y1 - 1997/6
N2 - The effects of short treatments (7 days) with clomipramine and fluvoxamine on the reactivity to inhalations of 35% CO2/65% O2 were compared in 39 panic patients who had positive responses to 35% CO2 inhalations. A double-blind, randomized, placebo-controlled design was applied. Each patient was given the 35% CO2 challenge on days 0 (before starting treatment), 3, and 7. Patients on placebo did not report any significant changes in their reactivity to 35% CO2 across the three sessions, whereas patients on clomipramine and fluvoxamine reported a significant attenuation of the reactivity on day 7. These results indicate that treatments with clomipramine and fluvoxamine decrease hypersensitivity to 35% CO2 after a few days, suggesting a relevant role of the modulation of CO2 sensitivity by the serotonergic system in antipanic properties of these compounds.
AB - The effects of short treatments (7 days) with clomipramine and fluvoxamine on the reactivity to inhalations of 35% CO2/65% O2 were compared in 39 panic patients who had positive responses to 35% CO2 inhalations. A double-blind, randomized, placebo-controlled design was applied. Each patient was given the 35% CO2 challenge on days 0 (before starting treatment), 3, and 7. Patients on placebo did not report any significant changes in their reactivity to 35% CO2 across the three sessions, whereas patients on clomipramine and fluvoxamine reported a significant attenuation of the reactivity on day 7. These results indicate that treatments with clomipramine and fluvoxamine decrease hypersensitivity to 35% CO2 after a few days, suggesting a relevant role of the modulation of CO2 sensitivity by the serotonergic system in antipanic properties of these compounds.
UR - http://www.scopus.com/inward/record.url?scp=0030910671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030910671&partnerID=8YFLogxK
U2 - 10.1097/00004714-199706000-00006
DO - 10.1097/00004714-199706000-00006
M3 - Article
C2 - 9169961
AN - SCOPUS:0030910671
SN - 0271-0749
VL - 17
SP - 173
EP - 178
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 3
ER -